Postsurgical chemo linked to survival gains in pancreatic cancer

10/8/2013 | U.S. News & World Report

Data on 354 patients with pancreatic cancer who underwent tumor removal showed those who took the chemotherapy drug gemcitabine had disease-free survival of 13.4 months, while those who did not receive treatment had survival of 6.7 months. The findings appear in the Journal of the American Medical Association.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ